RBC Capital Downgrades Cidara Therapeutics (CDTX) to Sector Perform

RBC Capital analyst Brian Abrahams downgraded Cidara Therapeutics (NASDAQ: CDTX) from Outperform to Sector Perform with a price target of $221.50 (from $145.00).

The analyst comments: "Today morning, MRK announced their intent to acquire CDTX for $221.50/share and a total deal size valued at ~$9.2B. Given the proposal, we are increasing our price target to $221.50 from $145 to reflect the deal terms and likely 1Q26 closing, and downgrading to Sector Perform as we expect the stock to trade roughly in line with the proposed acquisition price going forward."

For an analyst ratings summary and ratings history on Cidara Therapeutics click here. For more ratings news on Cidara Therapeutics click here.

Shares of Cidara Therapeutics closed at $217.71 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• AI/ML Innovations plans $2M private placement on the CSE
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery